In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau discuss an illustrative patient case to demonstrate how they individualize primary biliary cholangitis (PBC) therapy for patients ​with cirrhosis. Topics covered include:

• AASLD guideline recommendations for second-line therapy for PBC
• Considerations when using newer agents for second-line treatment of PBC in patients with cirrhosis: elafibranor and seladelpar

Presenters:

Stuart C. Gordon, MD 
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan

Nancy Reau, MD 
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
Chicago, Illinois

To learn more about PBC management, check out our program, 
Curbside Consults: Expert Insights on Challenges in PBC Management.

Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc